Halozyme (HALO) Q2 EPS Jumps 69%
Halozyme Therapeutics (NASDAQ:HALO) reported strong Q2 2025 results on August 5, with EPS of $1.54, exceeding the $1.24 consensus and ...
Wednesday, October 15, 2025
Tag: Halozyme
News Summarized. Time Saved. Bite-sized news briefs for busy people. No fluff, just facts.